2cureX AB

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0010468124
SEK
1.00
-0.3 (-23.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About 2cureX AB stock-summary
stock-summary
2cureX AB
Pharmaceuticals & Biotechnology
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Company Coordinates stock-summary
Company Details
C/o Mazars SET Revisionsbyra AB, Box 159 , LANDSKRONA None : 261 22
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Povl-Andre Bendz
Independent Chairman of the Board
Dr. Ole Thastrup
Deputy Chief Executive Officer, CSO, Executive Director
Ms. Camilla Huse Bondesson
Director
Dr. Joergen Drejer
Independent Director
Dr. Timm-H. Jessen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2023)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 30 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.06%

stock-summary
Debt Equity

-5.10

stock-summary
Return on Equity

-3,081.80%

stock-summary
Price to Book

30.25